Some HIV treatment regimens are very difficult for patients or care givers to manage and many documented drug failures have shown to be directly related to non-compliance. There are a number of ...

Raltegravir, the first INSTI, was originally approved for the management of HIV ... based regimen. In the STARTMRK trial, a double-blind, randomized, controlled non-inferiority trial in treatment ...

Injectable ART is administered to the gluteal muscle by a healthcare professional. Research might increase accessibility with ...

Descovy treats and helps prevent HIV in some people, but it isn’t used as PrEP for females. Find out why and what other ...

A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Adolescents who are treatment-naive had promising results when using dolutegravir/lamivudine as antiretroviral therapy over ...

Effective HIV management involves implementation ... Maintaining access to high-quality care by optimizing treatment regimens, decreasing delays in treatment initiation, and engaging patients ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.

"ART involves taking a combination of HIV medications (HIV treatment regimen) on a fixed schedule, usually once or twice a day. "ART is recommended for everyone with HIV. While it does not ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...